Cleo Diagnostics (COV.AX) Stock Price

Cleo Diagnostics Price

CLOSED
0.31
​
Market closed

Over the last 2 years Cleo Diagnostics grew revenue by 228.1% annually, reaching 1.18 M AUD. For Cleo Diagnostics, the net margin of -337.5% is up versus -1,571.1% a few years ago.

Cleo Diagnostics stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cleo Diagnostics business model & stock analysis

Cleo Diagnostics Ltd develops non-invasive blood-based IVD tests for ovarian cancer detection. The company's three-phased strategy includes the Triage Test for pre-surgical assessment of ovarian masses, the Recurrence Test for post-surgical monitoring of cancer recurrence, and the Screening Test for early detection in asymptomatic women. The CLEO Test Kit detects the protein biomarker CXCL10 in blood samples. These products target healthcare providers, oncologists, and diagnostic laboratories seeking advanced tools for ovarian cancer management. The company generates revenue through the sale of these diagnostic tests and kits to medical institutions and laboratories in Australia and potentially international markets. The Triage Test helps determine malignancy before oncologist referral, the Recurrence Test identifies cancer recurrence after surgery and chemotherapy, and the Screening Test enables early detection in symptom-free women. Cleo Diagnostics Ltd focuses on delivering these specialized tests to address unmet needs in ovarian cancer diagnostics. Revenue streams are derived from the commercialization of these three test phases and the CLEO Test Kit, targeting medical professionals and healthcare facilities requiring accurate and non-invasive diagnostic solutions.

Frequently asked questions about Cleo Diagnostics

Converted at the current exchange rate, the Cleo Diagnostics share trades at 0.19 EUR (0.31 AUD).

The revenue cannot currently be calculated for Cleo Diagnostics.

The profit of Cleo Diagnostics is -5.94 M AUD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Cleo Diagnostics is currently -7.04. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Cleo Diagnostics stock.

The P/S cannot be calculated for Cleo Diagnostics currently.

The Eulerpool Quality Score for Cleo Diagnostics is 2/10.

The ISIN of Cleo Diagnostics is AU0000288045. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Cleo Diagnostics is COV.AX. The ticker symbol is used to trade Cleo Diagnostics shares on the stock exchange.

Fair ValueTerminal
0.25 AUD
Over-/UndervaluationTerminal
Fairly valued
Sector
—
Industry
Other
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website cleodx.com
Country
Australia
Currency
AUD
Initial public offering
Aug 22, 2023
ISIN
AU0000288045
Cusip
Q2515F102
Market capitalization
41.74 M AUDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/Se
—
EV/EBIT
—
P/B Ratio
8.33
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-118.49 %
Last updated Oct 20, 2026, 9:35 AM

Cleo Diagnostics Peer Group

Cleo Diagnostics FIGI

COV:AU · BBG01HBC36S5COV:AT · BBG01HBC36T4COV:AH · BBG01HBC36Y8